215 related articles for article (PubMed ID: 32757962)
1. Cholangiocarcinoma: investigations into pathway-targeted therapies.
Ntanasis-Stathopoulos I; Tsilimigras DI; Gavriatopoulou M; Schizas D; Pawlik TM
Expert Rev Anticancer Ther; 2020 Sep; 20(9):765-773. PubMed ID: 32757962
[TBL] [Abstract][Full Text] [Related]
2. Novel targeted treatment options for advanced cholangiocarcinoma.
Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
Schweitzer N; Vogel A
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
[TBL] [Abstract][Full Text] [Related]
4. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.
Rahnemai-Azar AA; Pawlik TM
Expert Opin Investig Drugs; 2021 Apr; 30(4):419-427. PubMed ID: 33645382
[No Abstract] [Full Text] [Related]
5. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
[TBL] [Abstract][Full Text] [Related]
6. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
7. Medical treatment for cholangiocarcinoma.
Adeva J; Sangro B; Salati M; Edeline J; La Casta A; Bittoni A; Berardi R; Bruix J; Valle JW
Liver Int; 2019 May; 39 Suppl 1():123-142. PubMed ID: 30892822
[TBL] [Abstract][Full Text] [Related]
8. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of ivosidenib for the treatment of
Tella SH; Mahipal A
Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911
[TBL] [Abstract][Full Text] [Related]
10. Novel precision therapies for cholangiocarcinoma: an overview of clinical trials.
Uson Junior PLS; Bearss J; Babiker HM; Borad MJ
Expert Opin Investig Drugs; 2023 Jan; 32(1):69-75. PubMed ID: 36714945
[TBL] [Abstract][Full Text] [Related]
11. [Medical management of cholangiocarcinomas in 2015].
Marret G; Neuzillet C; Rousseau B; Tournigand C
Bull Cancer; 2016 Apr; 103(4):389-99. PubMed ID: 26922666
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapies for intrahepatic cholangiocarcinoma.
Kelley RK; Bridgewater J; Gores GJ; Zhu AX
J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma.
Sahin IH; Tan E; Kim R
Expert Opin Investig Drugs; 2021 Apr; 30(4):333-341. PubMed ID: 33378249
[TBL] [Abstract][Full Text] [Related]
14. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
Jensen LH; Jakobsen A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways and targeted therapy in cholangiocarcinoma.
Dabney RS; Khalife M; Shahid K; Phan AT
Clin Adv Hematol Oncol; 2019 Nov; 17(11):630-637. PubMed ID: 31851165
[TBL] [Abstract][Full Text] [Related]
16. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
Brown ZJ; Ruff SM; Pawlik TM
Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
[TBL] [Abstract][Full Text] [Related]
17. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs.
Marin JJ; Macias RI
Expert Opin Investig Drugs; 2021 Jul; 30(7):675-679. PubMed ID: 33934687
[No Abstract] [Full Text] [Related]
18. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
Rizzo A; Ricci AD; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
[TBL] [Abstract][Full Text] [Related]
19. Cholangiocarcinoma Therapeutics: An Update.
Nguyen MLT; Toan NL; Bozko M; Bui KC; Bozko P
Curr Cancer Drug Targets; 2021; 21(6):457-475. PubMed ID: 33563168
[TBL] [Abstract][Full Text] [Related]
20. Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials.
Bourien H; Lamarca A; McNamara MG; Hubner RA; Valle JW; Edeline J
Expert Opin Investig Drugs; 2021 Sep; 30(9):975-983. PubMed ID: 34420429
[No Abstract] [Full Text] [Related]
[Next] [New Search]